JW Pharmaceutical Corporation (KRX: 001060)
South Korea
· Delayed Price · Currency is KRW 24,250
+600 (2.54%)
Dec 18, 2024, 3:30 PM KST
JW Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 736,543 | 748,527 | 684,351 | 606,585 | 547,336 | 511,335 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | - | - | Upgrade
|
| Revenue | 736,543 | 748,527 | 684,351 | 606,585 | 547,336 | 511,335 | Upgrade
|
| Revenue Growth (YoY) | -0.02% | 9.38% | 12.82% | 10.83% | 7.04% | -4.81% | Upgrade
|
| Cost of Revenue | 401,807 | 412,984 | 396,397 | 372,209 | 369,810 | 350,216 | Upgrade
|
| Gross Profit | 334,735 | 335,542 | 287,955 | 234,376 | 177,526 | 161,119 | Upgrade
|
| Selling, General & Admin | 207,729 | 204,728 | 182,652 | 171,220 | 149,035 | 147,578 | Upgrade
|
| Research & Development | 34,814 | 33,671 | 33,736 | 19,884 | 22,943 | 25,220 | Upgrade
|
| Operating Expenses | 237,340 | 238,911 | 227,464 | 203,528 | 178,849 | 180,133 | Upgrade
|
| Operating Income | 97,396 | 96,631 | 60,490 | 30,848 | -1,323 | -19,014 | Upgrade
|
| Interest Expense | -10,470 | -12,562 | -9,387 | -7,337 | -7,587 | -11,279 | Upgrade
|
| Interest & Investment Income | 5,193 | 6,322 | 5,814 | 1,981 | 632.79 | 128.05 | Upgrade
|
| Earnings From Equity Investments | 1,723 | 621.06 | -955.41 | -1,149 | -1,924 | -369.17 | Upgrade
|
| Currency Exchange Gain (Loss) | -931.35 | -1,817 | -2,300 | -925.96 | -2,214 | 845.83 | Upgrade
|
| Other Non Operating Income (Expenses) | -6,660 | -36,102 | 5,425 | -1,191 | -777.66 | -4,581 | Upgrade
|
| EBT Excluding Unusual Items | 86,251 | 53,095 | 59,088 | 22,227 | -13,193 | -34,268 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2,966 | 2,830 | -8,908 | -646.8 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -21.81 | -1,088 | 3.28 | -1,048 | -12.24 | 18.15 | Upgrade
|
| Asset Writedown | - | - | -4,821 | - | - | -85 | Upgrade
|
| Pretax Income | 89,195 | 54,836 | 45,362 | 20,533 | -13,205 | -34,335 | Upgrade
|
| Income Tax Expense | 15,785 | 16,406 | 15,509 | 21,974 | 2,070 | -9,060 | Upgrade
|
| Earnings From Continuing Operations | 73,410 | 38,430 | 29,853 | -1,441 | -15,275 | -25,275 | Upgrade
|
| Minority Interest in Earnings | 0 | -1,424 | 2,039 | 473.6 | 34.19 | -0.14 | Upgrade
|
| Net Income | 73,410 | 37,006 | 31,892 | -967.85 | -15,241 | -25,275 | Upgrade
|
| Preferred Dividends & Other Adjustments | 3,690 | 516.84 | - | - | - | - | Upgrade
|
| Net Income to Common | 69,721 | 36,489 | 31,892 | -967.85 | -15,241 | -25,275 | Upgrade
|
| Net Income Growth | 192.75% | 16.04% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 57 | 23 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 23 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | 804.72% | 0.48% | 0.08% | -0.05% | 0.04% | -13.15% | Upgrade
|
| EPS (Basic) | 1216.51 | 1563.62 | 1373.14 | -41.70 | -656.37 | -1088.94 | Upgrade
|
| EPS (Diluted) | 1216.27 | 1563.62 | 1373.14 | -41.70 | -656.37 | -1088.94 | Upgrade
|
| EPS Growth | -69.27% | 13.87% | - | - | - | - | Upgrade
|
| Free Cash Flow | 86,361 | 59,871 | 46,845 | 10,657 | 50,667 | 46,246 | Upgrade
|
| Free Cash Flow Per Share | 1506.56 | 2565.56 | 2016.97 | 459.20 | 2182.01 | 1992.45 | Upgrade
|
| Dividend Per Share | 392.157 | 392.157 | - | - | - | - | Upgrade
|
| Gross Margin | 45.45% | 44.83% | 42.08% | 38.64% | 32.43% | 31.51% | Upgrade
|
| Operating Margin | 13.22% | 12.91% | 8.84% | 5.09% | -0.24% | -3.72% | Upgrade
|
| Profit Margin | 9.47% | 4.87% | 4.66% | -0.16% | -2.78% | -4.94% | Upgrade
|
| Free Cash Flow Margin | 11.73% | 8.00% | 6.85% | 1.76% | 9.26% | 9.04% | Upgrade
|
| EBITDA | 116,778 | 119,206 | 77,327 | 46,960 | 19,365 | 1,335 | Upgrade
|
| EBITDA Margin | 15.85% | 15.93% | 11.30% | 7.74% | 3.54% | 0.26% | Upgrade
|
| D&A For EBITDA | 19,382 | 22,575 | 16,836 | 16,112 | 20,688 | 20,349 | Upgrade
|
| EBIT | 97,396 | 96,631 | 60,490 | 30,848 | -1,323 | -19,014 | Upgrade
|
| EBIT Margin | 13.22% | 12.91% | 8.84% | 5.09% | -0.24% | -3.72% | Upgrade
|
| Effective Tax Rate | 17.70% | 29.92% | 34.19% | 107.02% | - | - | Upgrade
|
| Advertising Expenses | - | 22,690 | 22,673 | 18,416 | 15,067 | 17,555 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.